Elevated interleukin-6 (IL-6) levels have also been associated with worse clinical outcomes in patients with anti-MDA5-positive dermatomyositis and RP-ILD, further reinforcing IL-6 as a potential prognostic indicator in this subgroup [47]. The gene discussed is IL6; the disease is interstitial lung disease.